Sutro Biopharma STRO Operating Lease Liabilities
Operating Lease Liabilities at other companies
Other financials
Where this comes from
Reported directly by Sutro Biopharma in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityNoncurrent.
The official record: Sutro Biopharma’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about Sutro Biopharma's operating lease liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Sutro Biopharma's operating lease liabilities?
- Sutro Biopharma (STRO) reported operating lease liabilities of $6.03M in Q1 2026.
- How has Sutro Biopharma's operating lease liabilities changed year-over-year?
- Sutro Biopharma's operating lease liabilities decreased by 55.8% year-over-year, from $13.63M to $6.03M.
- What is the long-term trend for Sutro Biopharma's operating lease liabilities?
- Over 5 years (2020 to 2025), Sutro Biopharma's operating lease liabilities has grown at a -22.3% compound annual growth rate (CAGR), from $27.8M to $7.89M.
- What does operating lease liabilities mean?
- Long-term portion of operating lease obligations extending beyond one year, representing committed future rent payments.